Compare Kinder Morgan Inc (KMI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Kinder Morgan Inc is far larger — about 7.1× State Street SPDR S&P Biotech ETF's market cap, and Kinder Morgan Inc pays a 3.66% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KMI | XBI | |
|---|---|---|
Market Cap | $71.81B | $10.11B |
Volume | 16,921,908 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $34.31 | $169.55 |
52-Week Low | $25.84 | $104.99 |
Typical Hold Time | 150 Days | 38 Days |
Enterprise Value | $103.86B | — |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.49, up 2.11% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with revenue growth from $15.1B in 2024 to $16.94B in 2025 and net income margin expanding to 19.31%. Recent earnings beats and a $10B project backlog support growth prospects, while analyst consensus targets $37.20 with 47% buy ratings.
KMI presents a compelling investment case with stable fee-based revenues, dividend yield support, and natural gas infrastructure growth. Key risks include energy market volatility and high debt levels ($29.66B long-term). The stock offers upside potential from current levels but requires monitoring of cash flow sustainability and interest rate sensitivity.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
